| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d821543cc4e5f7c564c1e9c9a0573159 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate |
2017-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e076e7391434abb62dafc81745931822
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f28104a3eab834f414b39d801f48b957
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0600c4bac2dc603f00e58dea761eedab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5bd584141aeeebe4646610547d16a7b |
| publicationDate |
2019-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10383954-B2 |
| titleOfInvention |
Methods of inducing responsiveness to anti-angiogenic agent |
| abstract |
The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11191848-B2 |
| priorityDate |
2013-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |